Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

23.02 -0.46 (-1.96%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
49 50 Next >
News headline image
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
What's Going On With Hims & Hers Health Stock Monday? ↗
Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,... 
Via Benzinga
News headline image
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why ↗
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's... 
Via Benzinga
News headline image
Smart Money Is Betting Big In HIMS Options ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Could This Magnificent Pharma Stock 10x in the Next 5 Years? ↗
Disrupting pharmacies is just the start for Hims & Hers. 
Via The Motley Fool
News headline image
A Look Into Hims & Hers Health Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Hims & Hers Health? ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Hims & Hers Health ↗
 
Via Benzinga
News headline image
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
From Hims & Hers
Via Business Wire
News headline image
Top 3 Stocks Institutions Are Buying Right Now
Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks. 
Via MarketBeat
News headline image
Hims & Hers Stock Dropped: Here's What You Need to Know ↗
The GLP-1 drama continues at Hims & Hers. 
Via The Motley Fool
News headline image
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity' ↗
 
Via Benzinga
News headline image
Decoding 6 Analyst Evaluations For Hims & Hers Health ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health ↗
 
Via Benzinga
News headline image
What Is Going On With Hims & Hers Stock? ↗
Big GLP-1 news could have an impact. 
Via The Motley Fool
News headline image
Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers
From Hims & Hers
Via Business Wire
News headline image
Why Hims & Hers' Incredible Growth Will Continue ↗
GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is. 
Via The Motley Fool
News headline image
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk. ↗
Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide. 
Via Investor's Business Daily
News headline image
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move? ↗
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own... 
Via Benzinga
News headline image
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug ↗
An industry group sued the FDA, claiming tirzepatide remains in shortage. 
Via Investor's Business Daily
Topics Lawsuit
News headline image
Where Does Hims & Hers Stock Go From Here? ↗
Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright? 
Via The Motley Fool
News headline image
2 Incredibly Cheap Growth Stocks to Buy Right Now ↗
Look beyond the stock price at the business when shares are volatile. 
Via The Motley Fool
News headline image
2 No-Brainer Growth Stocks to Buy With $500 Right Now ↗
Consistently investing even moderate sums can grow your portfolio with time. 
Via The Motley Fool
News headline image
Top 3 Stocks with Explosive Call Option Activity: What to Watch
Three stocks reported a surge in call option buying recently, showing investors that there could be a path to more upside potential, analysts agree 
Via MarketBeat
News headline image
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List ↗
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
News headline image
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth. 
Via MarketBeat
Topics Stocks
News headline image
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock? ↗
Growth for its GLP-1 weight loss drugs continues to be robust. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.